SCHEMBL4099062

SCHEMBL4099062

CC(Br)C(=O)c1cccc2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.57
NR4A2 P43354 1/20 0.57
NR4A3 Q92570 1/20 0.57
PTPN1 P18031 1/20 0.55
PLK1 P53350 1/20 0.55
MMP3 P08254 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
CDC25B P30305 2/20 0.50
ALDH1A1 P00352 4/20 0.47
CYP1A2 P05177 3/20 0.47
CYP2C9 P11712 3/20 0.47
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 2/20 0.47
GMNN O75496 2/20 0.47
LMNA P02545 2/20 0.47
POLB P06746 2/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 2/20 0.47
MAPK1 P28482 2/20 0.47
BLM P54132 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6622009 0.86 NR4A1 (0.44) NR4A1NR4A2NR4A3PTPN1PLK1
SCHEMBL4109121 0.85 NR4A1 (0.53) NR4A1NR4A2NR4A3PTPN1PLK1
SCHEMBL5716814 0.84 NR4A1 (0.61) NR4A1NR4A2NR4A3PTPN1PLK1
SCHEMBL32665708 0.84 NR4A1 (0.61) NR4A1NR4A2NR4A3PTPN1PLK1
SCHEMBL2599098 0.82 NR4A1 (0.59) NR4A1NR4A2NR4A3PTPN1PLK1
SCHEMBL2599103 0.82 NR4A1 (0.59) NR4A1NR4A2NR4A3PTPN1PLK1
SCHEMBL25057402 0.81 NR4A1 (0.57) NR4A1NR4A2NR4A3PTPN1PLK1
SCHEMBL10358074 0.81 NR4A1 (0.57) NR4A1NR4A2NR4A3PTPN1PLK1
SCHEMBL6008119 0.81 NR4A1 (0.57) NR4A1NR4A2NR4A3PTPN1PLK1
SCHEMBL5125965 0.81 NR4A1 (0.57) NR4A1NR4A2NR4A3PTPN1PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10398028-B2 Surface treating composition for copper and copper alloy and utilization thereof SHIKOKU CHEMICALS CORPORATION (JP) 2019-08-27 US disclosed
US-20170064823-A1 SURFACE TREATING COMPOSITION FOR COPPER AND COPPER ALLOY AND UTILIZATION THEREOF SHIKOKU CHEMICALS CORPORATION (JP) 2017-03-02 US disclosed
US-9532493-B2 Surface treating composition for copper and copper alloy and utilization thereof SHIKOKU CHEMICALS CORPORATION (JP) 2016-12-27 US disclosed
EP-2714962-B1 SURFACE TREATING COMPOSITION FOR COPPER AND COPPER ALLOY AND UTILIZATION THEREOF SHIKOKU CHEM (JP) 2015-07-08 EP disclosed
US-20140097231-A1 SURFACE TREATING COMPOSITION FOR COPPER AND COPPER ALLOY AND UTILIZATION THEREOF SHIKOKU CHEMICALS CORPORATION (JP) 2014-04-10 US disclosed
US-8378116-B2 Phenylnaphthylimidazole compound and usage of the same SHIKOKU CHEMICALS CORPORATION (JP) 2013-02-19 US disclosed
EP-1753728-B1 PHENYLNAPHTHYLIMIDAZOLES FOR USE ON COPPER SURFACES DURING SOLDERING SHIKOKU CHEM (JP) 2012-12-19 EP disclosed
US-20120199385-A1 PHENYLNAPHTHYLIMIDAZOLE COMPOUND AND USAGE OF THE SAME SHIKOKU CHEMICALS CORPORATION (JP) 2012-08-09 US disclosed
US-8183386-B2 Phenylnaphthylimidazole compound and usage of the same SHIKOKU CHEMICALS CORPORATION (JP) 2012-05-22 US disclosed
US-20090221645-A1 Dihydroimidazothiazole Derivatives PROSIDION LIMITED (GB) 2009-09-03 US disclosed
EP-1474141-A1 5-HT2B RECEPTOR ANTAGONISTS Pharmagene Laboratories Ltd (GB) 2004-11-10 EP disclosed
US-20040010022-A1 5-HT2B receptor antagonists ASTERAND, INC. 2004-01-15 US disclosed
WO-2003068227-A1 5-HT2B RECEPTOR ANTAGONISTS PHARMAGENE LABORATORIES LIMITED (GB) 2003-08-21 WO disclosed
WO-2003068226-A1 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS PHARMAGENE LABORATORIES LIMITED (GB) 2003-08-21 WO disclosed
EP-0576350-B1 Branched alkylamino thiazole derivatives, process for their preparation and pharmaceutical compositions containing them SANOFI SA (FR) 1997-10-29 EP disclosed
US-5464847-A Moduators of corticotropin releasing factor ELF SANOFI (FR) 1995-11-07 US disclosed
EP-0576350-A1 Branched alkylamino thiozole derivatives, process for their preparation and pharmaceutical compositions containing them SANOFI (FR) 1993-12-29 EP disclosed
EP-0284297-B1 HALOGENATED NAPHTHALENE DERIVATIVES NIPPON OIL CO. LTD. (JP) 1990-12-27 EP disclosed
US-4803013-A IMPROVED DIELECTRIC PROPERTIES, HYDROGEN ABSORPTION, FLUIDITY, VISCOSITY STABILITY NIPPON OIL CO., LTD. (JP) 1989-02-07 US disclosed
EP-0284297-A1 Halogenated Naphthalene Derivatives NIPPON OIL CO. LTD. (JP) 1988-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221645-A1 Dihydroimidazothiazole Derivatives TPH1, HTR3B, HTR1A NR4A1 498/4885NR4A2 544/4885NR4A3 463/4885
US-10398028-B2 Surface treating composition for copper and copper alloy and utilization thereof SOD1, SOD3, AOC3 NR4A1 3115/4885NR4A2 3553/4885NR4A3 3259/4885
US-20040010022-A1 5-HT2B receptor antagonists HTR2B, HTR1B, HTR2C NR4A1 121/4885NR4A2 205/4885NR4A3 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.